从创新药到基因治疗、从诊断试剂到医疗器械，在广州，生物医药"黄埔军团"加速崛起。 12月15日，2025年广州独角兽创新企业榜单正式揭晓，全市共有210家企业入选。作为广州独角兽企业最密集的集聚地和广州科创"领头羊"，广州开发区、 黄埔区聚集了60家独角兽企业（占全市29%）。尤其在集成电路、生物医药、人工智能、新能源等领域形成产业集群，吸引了粤芯、艾佛光通、心航路、奥 动新能源等硬科技企业。 生物医药已经是黄埔区最鲜明的产业名片。就在12月12日，"广州开发区战略企业家培育计划——生物医药产业战略破局圆桌会"在黄埔区举办。自今年9月 以来，广州开发区、黄埔区就谋划启动"战略企业家培育计划"，有效整合政府、市场、专业机构等多方资源，通过系统化培育以提升企业竞争力和企业家经 营管理能力。 云舟生物就在此次圆桌会初步对接了从事不同环节的企业。云舟生物科技（广州）股份有限公司董事、执行总裁黄锐向智通财经表示，公司正在推进国际 化，更需要联合区内伙伴，共同打造"中国技术+全球市场"出海联合平台，而黄埔区开放、协同、互信的产业氛围，正是创新型企业所需要的发展土壤。 这家公司目前已发展为全球最大规模的科研级别基因载体CR ...

New IPOs and Listings - Two new stocks are available for subscription: Delijia (603092.SH) on the Shanghai Stock Exchange and Zhongcheng Consulting (920003.BJ) on the Beijing Stock Exchange [1] - Four stocks are listed today: Bibete (688759.SH), Xi'an Yicai (688783.SH), Heyuan Bio (688765.SH), and Taikaiying (920020.BJ) [1] Delijia (603092.SH) - Delijia specializes in the R&D, production, and sales of high-speed heavy-load precision gear transmission products, primarily for wind power generation [2][7] - The IPO price is 46.68 CNY per share, with an institutional offering price of 47.68 CNY, and a market capitalization of 16.8 billion CNY [5] - The company has a projected market share of 10.36% globally and 16.22% in China for wind power transmission equipment by 2024, ranking third globally and second in China [7] - Delijia's revenue from onshore wind power is expected to be 36.25 billion CNY in 2024, accounting for 98.57% of its total revenue [7] Zhongcheng Consulting (920003.BJ) - Zhongcheng Consulting focuses on engineering consulting services and has ranked among the top five in Jiangsu Province for engineering cost consulting revenue from 2021 to 2024 [8][11] - The IPO price is 14.27 CNY per share, with a market capitalization of 1.4 billion CNY [11] - The company plans to invest 1.23 billion CNY in building an engineering consulting service network and 0.77 billion CNY in R&D and information technology [11] Taikaiying (920020.BJ) - Taikaiying is the first company in the mining and construction tire segment to be listed on the Beijing Stock Exchange, recognized as the "first tire stock" on the exchange [15][19] - The IPO price is 7.50 CNY per share, with a market capitalization of 750 million CNY [18] - The company holds the number one market share in the domestic market for large-tonnage crane tires [19] Xi'an Yicai (688783.SH) - Xi'an Yicai is a leading manufacturer of 12-inch silicon wafers, ranking first in China and sixth globally in terms of production capacity [21][22] - The IPO price is 8.62 CNY per share, with a market capitalization of 34.81 billion CNY [21] - The company has a projected capacity of 120,000 wafers per month by 2026, which will meet 40% of the demand in mainland China [22] Heyuan Bio (688765.SH) - Heyuan Bio focuses on the research and development of plant-derived recombinant protein expression technology and has developed several pharmaceutical products [33][38] - The IPO price is 29.06 CNY per share, with a market capitalization of 10.39 billion CNY [35] - The company plans to invest 19.09 billion CNY in the construction of a plant for recombinant human serum albumin and 7.94 billion CNY in new drug development [37]